Kramvis A, Kew M C, Bukofzer S
Medical Research Council, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.
J Hepatol. 1998 Jan;28(1):132-41. doi: 10.1016/s0168-8278(98)80212-2.
BACKGROUND/AIM: The aim of this study was to sequence the precore region of HBV isolated from serum and tumorous and non-tumorous liver tissue from patients with hepatocellular carcinoma to identify mutations that might play a role in malignant transformation.
HBV DNA was extracted from 62 sera, 14 tumorous and 12 non-tumorous liver tissue samples of patients with hepatocellular carcinoma, amplified by the polymerase chain reaction and sequenced directly.
Thirty-nine patients were HBeAg-negative and 23 HBeAg-positive. Missense mutations were present predominantly in HBeAg-negative sera. The most common missense mutation, a guanine to thymine transversion, occurred at nucleotide 1862 in the bulge of the encapsidation signal; it was more prevalent in HBeAg-negative (10/39) than in HBeAg-positive patients (1/23) (p = 0.03). Mutations known to prevent HBeAg synthesis were detected in seven sera; five with an 1896 stop-codon mutation, one with an 1817 nonsense mutation, and one with a frameshift mutation caused by an insertion between 1838 and 1839. Missense mutations and deletions were present more often in tumorous tissue derived from HBsAg-negative patients. In the tumours missense mutations occurred at position 1862 and 1899, and the deletions affected direct repeat 1 and/or the encapsidation signal and included the x gene stop-codon.
The 1862 mutation, and other missense mutations and deletions detected in the precore gene, may disrupt HBV DNA replication and/or signal peptide cleavage leading to HBeAg-negativity. Disruption of viral replication may promote integration of unencapsidated replicative intermediates and hence contribute to hepatocarcinogenesis.
背景/目的:本研究旨在对从肝细胞癌患者血清、肿瘤性及非肿瘤性肝组织中分离出的乙肝病毒(HBV)前核心区进行测序,以鉴定可能在恶性转化中起作用的突变。
从62例肝细胞癌患者的血清、14份肿瘤性肝组织样本和12份非肿瘤性肝组织样本中提取HBV DNA,通过聚合酶链反应进行扩增并直接测序。
39例患者HBeAg阴性,23例HBeAg阳性。错义突变主要存在于HBeAg阴性血清中。最常见的错义突变是鸟嘌呤到胸腺嘧啶的颠换,发生在包装信号凸起处的核苷酸1862;在HBeAg阴性患者(10/39)中比在HBeAg阳性患者(1/23)中更普遍(p = 0.03)。在7份血清中检测到已知可阻止HBeAg合成的突变;5份有1896位终止密码子突变,1份有1817位无义突变,1份有由1838和1839之间插入导致的移码突变。错义突变和缺失在HBsAg阴性患者的肿瘤组织中更常见。在肿瘤中,错义突变发生在1862和1899位,缺失影响直接重复序列1和/或包装信号,并包括x基因终止密码子。
1862位突变以及在前核心基因中检测到的其他错义突变和缺失,可能会破坏HBV DNA复制和/或信号肽切割,导致HBeAg阴性。病毒复制的破坏可能促进未包装的复制中间体的整合,从而导致肝癌发生。